Physical activity may be effective in mitigating cancer-related cognitive impairment. Prior studies show this may be a promising treatment. However, sample sizes were small and self-reported measures varied.
Physical activity may be effective in mitigating cancer-related cognitive impairment. Prior studies show this may be a promising treatment. However, sample sizes were small and self-reported measures varied.
Researchers from the University of Illinois at Urbana-Champaign, in collaboration with other researchers across the country, examined its effectiveness among 299 breast cancer survivors with a mean age of 57.
The women wore an accelerometer for 7 consecutive days to measure their average daily minutes of moderate-to-vigorous physical activity. They also completed questionnaires and neuropsychological tests via an iPad application to measure fatigue and cognitive function.
Cognitive function was modeled as two latent factors—executive function and working memory—comprising performance across 7 cognitive tasks. Moderate-to-vigorous physical activity was associated with less fatigue, which was associated with faster times on executive function tasks and greater accuracy on working memory tasks.
Although the researchers concluded that there is a need for additional research in this area, they recommend physical activity for patients.
Study findings are available at https://link.springer.com/article/10.1007/s10549-017-4363-9.
FDA Approves T-DXd for Previously Treated HER2-Low and -Ultralow Metastatic Breast Cancer
Published: January 27th 2025 | Updated: January 28th 2025T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy in the metastatic setting.
ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer
January 26th 2025While ctDNA positivity was linked to worse overall disease-free survival (DFS) in stage III resected colon cancer, it was associated with significantly improved DFS with celecoxib compared to placebo.